• Login
    View Item 
    •   Home
    • Research, Student
    • Theses and Dissertations
    • View Item
    •   Home
    • Research, Student
    • Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MercerCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    About URSA

    Collecting PolicyLicense AgreementDigitization SpecificationsRemoval PolicyHarmful Language Statement

    Statistics

    Display statistics

    Characterization of Attenuated HSV-2 Mutants as Potential Vaccine Candidates Against Genital Herpes

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Garza_mercer_1160N_10366.pdf
    Size:
    1.302Mb
    Format:
    PDF
    Download
    Average rating
     
       votes
    Cast your vote
    You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.
    Star rating
     
    Your vote was cast
    Thank you for your feedback
    Author
    Garza, Bret Kevin
    Keyword
    Virology
    Microbiology
    Biomedical engineering
    Attenuated
    Herpes simplex
    Ribonucleotide reductase
    Thymidine kinase
    UL24
    Vaccine
    School of Medicine
    Date
    2021
    
    Metadata
    Show full item record
    URI
    http://hdl.handle.net/10898/12790
    Title
    Characterization of Attenuated HSV-2 Mutants as Potential Vaccine Candidates Against Genital Herpes
    Abstract
    A prophylactic and therapeutic vaccine against herpes simplex virus type 2 (HSV-2) infection is necessary to reduce the global disease burden of HSV-2 diseases. Subunit, single-cycle, and DNA vaccines have been studied in pre-clinical and clinical trials but have not been approved mostly due to lack of sufficient efficacy. Using targeted mutagenesis, a live, attenuated HSV-2 could be a likely candidate for a protective vaccine. In this study, we constructed and characterized two novel HSV-2 mutant strains, TKBAC /∆UL24 and TKBAC /∆UL39, that have loss-of-function in genes that are associated with viral pathogenesis. Bacterial artificial chromosome (BAC) technology and recombineering were used for construction of these strains and their revertants, TKBAC /UL24R and TKBAC /UL39R. ∆UL24 and ∆UL39 have internal deletions and TKBAC (the parent virus) has an insertion within the viral thymidine kinase gene consisting of the 7.5 kb BAC sequence. Sequencing of ∆UL24 and ∆UL39 confirmed the expected deletions with the HSV-2 UL24 and UL39 genes while the flanking regions remained intact. BAC DNAs were digested with select restriction endonucleases and fractionated by agarose gel electrophoresis. All constructs showed a similar digestion pattern compared to the parent strain, TKBAC, suggesting the mutant genomes were stable. Mutagenized BACS were used to create infectious virus stocks after transfection into Vero cells. We demonstrated that TKBAC /∆UL24 and TKBAC /∆UL39 were replication-competent in Vero cells. An HSV-2 UL24 mutant was shown to be a potential attenuated vaccine candidate in previous studies. The double mutant containing disruption of the TK gene would provide for an even safer attenuated vaccine candidate that would be less like to reactivate from latency and cause disease. Replication characteristics including a reduction in plaque size for TKBAC /∆UL39 suggested that this virus was crippled in vitro, while TKBAC /∆UL24 demonstrated similar replication characteristics to the parent strain. In vitro plaque reduction assays and viral yield assays against acyclovir suggest that TKBAC /∆UL39 is more sensitive to acyclovir compared to the parent strain, based on a lower IC50. Based on previous studies with individual TK or UL39 mutants, the double mutant should be even more deficient in the establishment of and reactivation from latency. Based on these results, TKBAC /∆UL24 and TKBAC /∆UL39 should be considered for further preclinical evaluation (in animal models) as viable candidates for a protective, safe prophylactic and therapeutic vaccine.
    Collections
    Theses and Dissertations

    entitlement

     

    DSpace software (copyright © 2002 - 2022)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.